These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 30971509)

  • 21. Ponatinib in Philadelphia chromosome-positive leukemias.
    Cortes JE; Talpaz M; Kantarjian H
    N Engl J Med; 2014 Feb; 370(6):577. PubMed ID: 24499221
    [No Abstract]   [Full Text] [Related]  

  • 22. Phase II trial of ponatinib in patients with chronic myeloid leukemia resistant to one previous tyrosine kinase inhibitor.
    Sanford D; Kantarjian H; Skinner J; Jabbour E; Cortes J
    Haematologica; 2015 Dec; 100(12):e494-5. PubMed ID: 26341741
    [No Abstract]   [Full Text] [Related]  

  • 23. Ponatinib in the treatment of chronic myeloid leukemia and philadelphia chromosome positive acute lymphoblastic leukemia.
    Pavlovsky C; Chan O; Talati C; Pinilla-Ibarz J
    Future Oncol; 2019 Jan; 15(3):257-269. PubMed ID: 30251548
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of dasatinib against ponatinib-resistant chronic myeloid leukemia cells.
    Okabe S; Tanaka Y; Moriyama M; Gotoh A
    Leuk Lymphoma; 2020 Jan; 61(1):237-239. PubMed ID: 31502898
    [No Abstract]   [Full Text] [Related]  

  • 25. Fatal progressive cerebral ischemia in CML under third-line treatment with ponatinib.
    Mayer K; Gielen GH; Willinek W; Müller MC; Wolf D
    Leukemia; 2014 Apr; 28(4):976-7. PubMed ID: 24170029
    [No Abstract]   [Full Text] [Related]  

  • 26. Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee.
    Januzzi JL; Garasic JM; Kasner SE; McDonald V; Petrie MC; Seltzer J; Mauro M; Croce K; Berman E; Deininger M; Hochhaus A; Pinilla-Ibarz J; Nicolini F; Kim DW; DeAngelo DJ; Kantarjian H; Xu J; Hall T; Srivastava S; Naranjo D; Cortes J
    J Hematol Oncol; 2022 Jan; 15(1):1. PubMed ID: 34991679
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ichthyosiform Reaction Related to Ponatinib Therapy.
    Fernández-González P; Buendía-Castaño D; Saceda-Corralo D; Jaen-Olasolo P
    Actas Dermosifiliogr (Engl Ed); 2019 Dec; 110(10):873-875. PubMed ID: 31493826
    [No Abstract]   [Full Text] [Related]  

  • 28. Pityriasis Rubra Pilaris-Like Reaction Induced by a Tyrosine Kinase Inhibitor, the Ponatinib.
    Mongereau M; Hillion B; Fouillard L; Boivin JF; Gaudron S
    Am J Dermatopathol; 2021 May; 43(5):394-395. PubMed ID: 33264130
    [No Abstract]   [Full Text] [Related]  

  • 29. Low-dose ponatinib is a good option in chronic myeloid leukemia patients intolerant to previous TKIs.
    Iurlo A; Cattaneo D; Malato A; Accurso V; Annunziata M; Gozzini A; Scortechini AR; Bucelli C; Scalzulli E; Attolico I; Maggi A; Martino B; Caocci G; Abruzzese E; Pregno P; Luciano L; Breccia M
    Am J Hematol; 2020 Oct; 95(10):E260-E263. PubMed ID: 32557788
    [No Abstract]   [Full Text] [Related]  

  • 30. The accelerated approval of oncologic drugs: lessons from ponatinib.
    Prasad V; Mailankody S
    JAMA; 2014 Jan 22-29; 311(4):353-4. PubMed ID: 24449310
    [No Abstract]   [Full Text] [Related]  

  • 31. Effectiveness and management of ponatinib as second-line treatment in chronic myeloid leukemia: an analysis from the monitoring registries of the Italian medicines agency (AIFA).
    Breccia M; Olimpieri PP; Celant S; Olimpieri OM; Pane F; Iurlo A; Summa V; Corradini P; Russo P
    Ann Hematol; 2023 May; 102(5):1257-1259. PubMed ID: 36914888
    [No Abstract]   [Full Text] [Related]  

  • 32. Ponatinib--a step forward in overcoming resistance in chronic myeloid leukemia.
    Frankfurt O; Licht JD
    Clin Cancer Res; 2013 Nov; 19(21):5828-34. PubMed ID: 23935038
    [TBL] [Abstract][Full Text] [Related]  

  • 33. BCR-ABL-positive acute myeloid leukemia: About one case treated with ponatinib.
    Maël H; Audrey B; Evelyne CB; Pierre-Yves D; Kaddour C; Gilles S; Arnaud P
    Ann Hematol; 2017 Feb; 96(2):335-336. PubMed ID: 27761606
    [No Abstract]   [Full Text] [Related]  

  • 34. Addendum to the German Consensus Recommendations on Ponatinib in the Treatment of Chronic Myeloid Leukemia.
    Saussele S; La Rosée P; Kiani A; Haverkamp W; Jentsch-Ullrich K; Stegelmann F; Rieger C; Waller CF; Franke GN; Junghanss C; Kirchmair R; Theurl M; le Coutre P
    Acta Haematol; 2024; 147(3):344-351. PubMed ID: 37848002
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The current status of ponatinib in the treatment of chronic myeloid leukemia.
    Deininger M
    Clin Adv Hematol Oncol; 2014 May; 12(5):329-31. PubMed ID: 25003490
    [No Abstract]   [Full Text] [Related]  

  • 36. Should vascular effects of newer treatments be addressed more completely?
    Yang EH; Watson KE; Herrmann J
    Future Oncol; 2015; 11(14):1995-8. PubMed ID: 26198824
    [No Abstract]   [Full Text] [Related]  

  • 37. In brief: ponatinib (Inclusig) returns.
    Med Lett Drugs Ther; 2014 Jan; 56(1434):8. PubMed ID: 24457561
    [No Abstract]   [Full Text] [Related]  

  • 38. Ponatinib in the therapy of chronic myeloid leukemia.
    Poch Martell M; Sibai H; Deotare U; Lipton JH
    Expert Rev Hematol; 2016 Oct; 9(10):923-32. PubMed ID: 27590270
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ponatinib reduces viability, migration, and functionality of human endothelial cells.
    Gover-Proaktor A; Granot G; Shapira S; Raz O; Pasvolsky O; Nagler A; Lev DL; Inbal A; Lubin I; Raanani P; Leader A
    Leuk Lymphoma; 2017 Jun; 58(6):1455-1467. PubMed ID: 27733071
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Overcoming resistance to targeted anticancer drugs.
    Doroshow JH
    N Engl J Med; 2013 Nov; 369(19):1852-3. PubMed ID: 24180495
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.